Ciclesonide

Evidence Level: L5

Predicted Indications: 5

Ciclesonide

Pharmacist Assessment Report

Ciclesonide: Inhaled corticosteroid prodrug → Atopic eczema (atopic eczema)

One-Sentence Summary

Ciclesonide is an inhaled corticosteroid prodrug that is converted in the body to an active glucocorticoid. The TxGNN model predicts it may be effective for atopic eczema, but no clinical trials and no publications directly studying this disease were found, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	atopic eczema
TxGNN Prediction Score	0.9996
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for ciclesonide is not available in the data compiled for this report. Based on its drug class, ciclesonide is a prodrug that is activated to des-ciclesonide, a glucocorticoid receptor agonist with anti-inflammatory effects.

Corticosteroids are an established treatment class for atopic eczema, an inflammatory skin disease. This makes the prediction mechanistically plausible. However, this reasoning is by class analogy only. No study of ciclesonide itself in atopic eczema was supplied.

Ciclesonide is an inhaled product. Use on the skin, or systemically, would need separate formulation, route and safety evaluation. Route compatibility has not yet been assessed.

Two other model outputs, “dermatitis, atopic” and “2-hydroxyethyl methacrylate sensitization”, also have no supporting studies. The “dermatitis, atopic” entry is essentially the same condition as the main prediction and should be consolidated with it in later review.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for atopic eczema.

Two items were found for other conditions. They do not study atopic eczema and do not raise the evidence level:

PMID	Year	Type	Journal	Key Findings
25515181	2015	Guideline/Review	Basic & Clinical Pharmacology & Toxicology	Finnish guideline on diagnosis and drug treatment of stable COPD. Indirect; it does not test ciclesonide.
22957490	2012	Case report	Contact Dermatitis	Systemic allergic dermatitis caused by inhaled budesonide, with cross-reactivity in patch tests to ciclesonide. This is a hypersensitivity signal, not evidence of benefit.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02285614	ALVESCO	Not recorded	Not recorded
02285606	ALVESCO	Not recorded	Not recorded
02303671	OMNARIS	Not recorded	Not recorded

Safety Considerations

Drug interactions: 63 interactions were identified. Examples of the main ones:

Major: Cladribine
Moderate: Clarithromycin, Miconazole, Cobicistat, Atazanavir, Fosamprenavir, Amprenavir, Boceprevir, Ceritinib, Conivaptan, Fostamatinib, inhaled rapid-acting human insulin, topical Abametapir
Minor: Formoterol, Salbutamol, Arformoterol

Several of the moderate interactions involve strong CYP3A4 inhibitors (for example clarithromycin, cobicistat and the HIV protease inhibitors). These can raise corticosteroid exposure.

Conditions of concern for corticosteroids as a class (not taken from the product label): herpes simplex keratitis, adrenocortical insufficiency, Addison disease, osteoporosis, fungal and parasitic infections, dermatophytosis, ocular hypertension and glaucoma.

Hypersensitivity: A published case report describes cross-reactivity between inhaled budesonide and ciclesonide in patch testing, so allergic contact reactions should be considered.

Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high (0.9996), and corticosteroids are mechanistically relevant to atopic eczema. However, no trial or publication studies ciclesonide in this disease, so the evidence level is L5. The available literature includes a hypersensitivity signal.

To proceed, the following is needed:

Studies or trials of ciclesonide, or its active metabolite, in atopic eczema
Mechanism-of-action data from DrugBank
Health Canada package insert warnings and contraindications
Assessment of route and formulation, since the marketed products are inhaled or nasal
Review of the comparative benefit of established topical corticosteroids already used in atopic eczema
Consolidation of the duplicate “atopic eczema” and “dermatitis, atopic” predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.